OCA
RCUS icon

Octagon Capital Advisors’s Arcus Biosciences RCUS Stock Holding History

Octagon Capital Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,868,000
Closed -$35.7M – 62
2023
Q4 		$35.7M Sell
1,868,000
-100,000
-5% -$1.6M 5.71% 5
2023
Q3 		$35.3M Hold
1,968,000
– – 5.43% 6
2023
Q2 		$40M Sell
1,968,000
-204,000
-9% -$3.88M 5.56% 4
2023
Q1 		$39.6M Sell
2,172,000
-310,700
-13% -$5.94M 5.7% 5
2022
Q4 		$51.3M Sell
2,482,700
-185,616
-7% -$5.11M 7.99% 4
2022
Q3 		$69.8M Sell
2,668,316
-1,658
-0.1% -$43.8K 12.05% 2
2022
Q2 		$67.7M Buy
2,669,974
+180,000
+7% +$4.41M 18.06% 2
2022
Q1 		$78.6M Buy
2,489,974
+394,743
+19% +$13.2M 16.99% 2
2021
Q4 		$84.8M Buy
2,095,231
+1,125,067
+116% +$43.6M 16.5% 2
2021
Q3 		$33.8M Buy
970,164
+210,000
+28% +$6.54M 8.33% 4
2021
Q2 		$20.9M Buy
760,164
+360,164
+90% +$10.3M 4.32% 5
2021
Q1 		$11.2M Buy
400,000
+100,000
+33% +$3.48M 4.23% 10
2020
Q4 		$7.79M Buy
+300,000
New +$7.26M 2.7% 15

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Octagon Capital Advisors's RCUS Position: Q1 2024 in Review

Octagon Capital Advisors sold out of Arcus Biosciences (RCUS) in Q1 2024, closing a stake of 1,868,000 shares — an estimated $35.7M sold.

Octagon Capital Advisors first reported a position in RCUS in Q4 2020 and held it in 13 quarters. The position peaked at $84.8M in Q4 2021. 172 funds tracked by Wall St. Rank hold RCUS as of Q1 2024.

  • Octagon Capital Advisors reported no remaining Arcus Biosciences position as of Q1 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 1,868,000 Arcus Biosciences shares in Q1 2024, an estimated $35.7M.
  • Octagon Capital Advisors first reported a position in Arcus Biosciences in Q4 2020 and held it in 13 quarters.
  • Octagon Capital Advisors's Arcus Biosciences position peaked at $84.8M in Q4 2021.
  • 172 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2024.

Based on Octagon Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.